Recombinant HIV-1 Envelope Protein for Vaccine Use - Licensing and Collaboration Opportunity

Researchers at the Vaccine Research Center (“VRC”) have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation. The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response.

 In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1.  Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.

The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response.  The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

  • Vaccine for prevention of HIV-1 infection.

  • Therapeutic vaccine for treatment of HIV-1 infection.

Competitive Advantages:

  Currently, no licensed HIV-1 vaccine exists.

Development Stage:

  • In vitro studies characterizing the immunogen and its interaction with HIV antibodies

  • In vivo results including immunogenicity in rabbits and guinea pigs, neutralizing activity of resulting serum

 

Inventors:  Peter D. Kwong (NIAID), Ivelin S. Georgiev (NIAID), Michael Gordon Joyce (NIAID), Marie L. Pancera (NIAID), Tongqing Zhou (NIAID), Priyamvada Acharya (NIAID), Jason J. Gorman (NIAID), Yongping Yang (NIAID), Aliaksandr A. Druz (NIAID), Guillaume Stewart-Jones (NIAID), Rita Chen (NIAID), Gwo-Yu Chuang (NIAID), Ulrich Baxa (NIAID), John R. Mascola (NIAID), Rebecca M. Lynch (NIAID), Baoshan Zhang (NIAID), Cheng Cheng (NIAID).

Intellectual Property:
US Application No. 62/046,059
US Application No. 62/136,480
PCT Application No. PCT/US2015/048729
US Application No. 15/508,885

Publications:  Pancera M, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-61. [PMID: 25296255].

Collaborative Research and Licensing Opportunity:  The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV-1 immunogens for treating or preventing HIV-1 infection.  For collaboration opportunities, please contact Dr. Barry Buchbinder, 240-627-3674; barry.buchbinder@nih.gov.


NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.